Get the Stockscreener App
0.7517
3.63%
-0.0283
Pre-market:
.75
-0.0017
-0.23%
Matinas Biopharma Holdings Inc stock is traded at $0.7517, with a volume of 39,320.
It is down -3.63% in the last 24 hours and up +33.99% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.78
Open:
$0.79
24h Volume:
39,320
Relative Volume:
0.28
Market Cap:
$4.82M
Revenue:
$1.10M
Net Income/Loss:
$-11.23M
P/E Ratio:
-0.3712
EPS:
-2.025
Net Cash Flow:
$-6.61M
1W Performance:
-8.33%
1M Performance:
+33.99%
6M Performance:
+2.97%
1Y Performance:
-10.51%
1-Day Range:
$0.7384
$0.79
1-Week Range:
$0.70
$0.856
52-Week Range:
$0.48
$3.09
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.7517 | 4.82M | 1.10M | -11.23M | -6.61M | -2.025 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
MTNB Q4 2024 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineEarnings Manipulation Risk - newsline.com
MTNB Q4 2024 Earnings: EPS Beats Estimates as Biotech Continues Clinical DevelopmentEarnings Analysis - newsline.com
MTNB Q4 2024 Earnings: EPS Surprise Beat Amidst Pre-Revenue ChallengesMid-Term Outlook - newsline.com
Matinas Biopharma (MTNB) Slips to $0.79 as Stock Tests Key Support LevelExtension Target - newsline.com
MTNB Q4 2024 Earnings: Narrower-than-Expected Loss Boosts Investor SentimentEarnings Call Q&A - newsline.com
MSN Money - MSN
MTNB Stock Price, Quote & Chart | MATINAS BIOPHARMA HOLDINGS I (NYSEARCA:MTNB) - ChartMill
Matinas Biopharma (MTNB) Holds Near Support Amid Cautious Market SentimentAndrews Pitchfork - newsline.com
MTNB Q4 2024 Earnings: Narrowing Losses Surprise as Biotech Advances Pipeline Without RevenueEarnings Per Share - The Legal Advocate
MTNB Q4 2024 Earnings: Narrowed Loss Beats Estimates as Matinas Advances PipelineProfit Recovery Report - newsline.com
MTNB Q4 2024 Earnings: Matinas Biopharma Reports Narrower-Than-Expected LossAnalyst Consensus Shift - Newser
MTNB Technical Analysis | Trend, Signals & Chart Patterns | MATINAS BIOPHARMA HOLDINGS I (NYSEARCA:MTNB) - ChartMill
Matinas Biopharma Holdings, Inc. Common Stock (NY: MTNB - The Chronicle-Journal
TradingKey - TradingKey
What Matinas (MTNB) is building for next year | Q4 2024: Earnings Beat EstimatesProfessional Trade Ideas - Newser
Matinas BioPharma (NYSE: MTNB) warns on going concern amid low cash and NYSE notice - Stock Titan
The edge Matinas (MTNB) has in a competitive landscape (-1.09%) 2026-05-08Real Trader Insights - Newser
What Matinas (MTNB) does that makes it resilient (Institutional Selling) 2026-05-08Social Momentum Signals - newser.com
Net current asset value per share of Matinas BioPharma Holdings, Inc. – FWB:6LJ0 - TradingView
Operating cash flow per share of Matinas BioPharma Holdings, Inc. – FWB:6LJ0 - TradingView
Matinas BioPharma Holdings, Inc. (MTNB) - Minichart
Sell Signal: Will Matinas BioPharma Holdings Inc benefit from government policy2026 Bull vs Bear & Expert Curated Trade Setups - baoquankhu1.vn
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):